Search Results - carol+feghali-bostwick

1 Results

Sort By:

Antifibrotic effects of oxetanyl sulfoxides

Technology: Currently, there are only two approved therapies for Idiopathic Pulmonary Fibrosis (IPF), pirfenidone and nintedanib, which are minimally effective at slowing the disease. These treatments are not effective at all in halting or reversing the progression of IPF. Therefore, there remains a great need for more effective therapies. Researchers...

Published: 6/24/2024 | Inventor(s): Carol Feghali-Bostwick, Peter Wipf

Keywords(s):

Category(s): BioPharma